Alluvi, known as BI 4744, presents a significant breakthrough in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/